echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > There is another batch of common medicine, the hospital can not sell

    There is another batch of common medicine, the hospital can not sell

    • Last Update: 2020-11-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical Network Industry Dynamics" Recently, Jiangsu Province Public Resources Trading Center issued "on the public suspension of procurement part of the failure to evaluate the quality and efficacy of generic drugs" (hereinafter referred to as "Notice").
    according to the Notice, a large number of large varieties of drugs, such as azithromycin tablets, ibuprofen particles, o nitrogen flat tablets, Malay acid inapuri tablets, hydrochloride bromine tablets, etc., will be suspended from procurement.
    , Achimycin for the second batch of band procurement varieties, O nitrogen flat tablets, Malay acid Inapri tablets for the first batch of band procurement involved varieties.
    , in fact, this is not the first time Jiangsu Province made a decision to suspend the procurement of drugs that have not been evaluated.
    April 17 this year, jiangsu Province Public Resources Trading Center has issued a "public suspension of procurement of some of the drugs not through generic drug quality and efficacy consistent evaluation of the drug notice."
    Among them, the suspension of the procurement of 152 drugs, including amosicillin capsules, omeprazole intestinal capsules, oxalic acid aspiropram tablets, meloxicon tablets, sodium bicarbonate tablets, cephalosporine capsules, left ethyl iracetam tablets and many other large varieties of drugs, involving national medicine, medicine, shi si medicine, North China Pharmaceuticals and many other pharmaceutical companies.
    In addition, according to incomplete statistics, for some time, Guangxi, Shanghai, Jiangsu, Beijing, Shenzhen, Liaoning and other more than 20 provinces for the non-consistent evaluation of drugs also frequently issued a suspension of trading qualification notice.
    that in April 2020 alone, Jiangsu, Beijing, Guangdong and other places have suspended the procurement of drugs that have not passed the consistent evaluation, which has involved nearly a thousand varieties, more than 500 pharmaceutical companies affected.
    As in a notice from Guangxi, 708 drugs were suspended for non-conformity evaluation, and in a notice in Beijing in April, 843 drugs were suspended for non-conformity evaluation.
    , for some of the varieties that have not been consistently evaluated, Shanghai is more in a job tip, or stop procurement and health insurance settlement.
    the above, with the deepening of drug review and approval system reform, consistent evaluation has become a prerequisite for participation in volume procurement.
    and many of the products that have not been evaluated consistently have been suspended, are drugs with the common name of the national collection varieties.
    industry believes that, according to the current policy direction, generic drugs can not participate in the national drug collection has been a dead end.
    not only did the company lose 70 per cent of the market share of medical institutions, but more crucially, it would only be used by doctors if prices were reduced to the same level in the future.
    the future, although the enterprise has not been evaluated also has the opportunity to be included in the centralized procurement, but the price range is very large, and vulnerable to policy impact, was removed from the network.
    , from the policy trend, it is still imperative for enterprises to speed up the adoption of consistent evaluation.
    for the vast majority of generic drug companies, future consistency evaluation will be the legal basis for all future market actions.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.